Myeloma Novel Drug Discovery ver 1.2
Research type
Research Study
Full title
Investigation of the activity of novel compounds for the treatment of myeloma and mechanisms of drug resistance to current therapies
IRAS ID
263630
Contact name
Charlotte Pawlyn
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. We are committed to improving our understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this we plan to collect samples of blood and bone marrow from patients so that we can use them to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some currently used treatments not working.
REC name
London - Stanmore Research Ethics Committee
REC reference
20/LO/0502
Date of REC Opinion
16 Apr 2020
REC opinion
Favourable Opinion